Skip to main content
Erschienen in: European Spine Journal 12/2016

23.09.2015 | Original Article

In chordoma, metastasis, recurrences, Ki-67 index, and a matrix-poor phenotype are associated with patients’ shorter overall survival

verfasst von: Adrian von Witzleben, Lukas T. Goerttler, Jochen Lennerz, Stephanie Weissinger, Marko Kornmann, Regine Mayer-Steinacker, Alexandra von Baer, Markus Schultheiss, Peter Möller, Thomas F. E. Barth

Erschienen in: European Spine Journal | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To establish a chordoma tissue cohort (n = 43) and to correlate localization, size, metastasis, residual disease (R-status), recurrences, histological subtype, matrix content, and Ki-67 proliferation index with patients’ overall survival (OS).

Methods and results

We used routine histopathology supplemented by immunohistochemistry. In our patient cohort (median age 69 years, range 17 to 84 years) the median OS was 8.25 years. 24 chordomas were localized in the sacrum, 6 in lumbar vertebrae, 7 in thoracic and cervical vertebrae, 5 were limited to the clivus, and one was localized in the nasal septum. Ten patients had metastases, with pulmonary, nodal, and hepatic involvement. 23 patients had recurrent disease. 23 chordomas were classified as ‘not otherwise specified’ (NOS). Besides NOS, we found the following differentiation patterns: renal cell cancer like in six cases, chondroid in four cases, hepatoid differentiation in three cases, and anaplastic morphology in six cases. Ki-67 index of ≥10 %, presence of metastasis, and the low content of extracellular matrix were statistically linked to poor OS (p < 0.05). The matrix-poor phenotype had a higher Ki-67 index (p < 0.05). Furthermore, presence of metastasis was associated with a higher Ki-67 index in the primary lesion, a positive resection margin, and multiple recurrences (p < 0.05 each).

Conclusion

We propose to include these parameters in the final pathologic report of the resected chordoma.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Bergh P, Kindblom LG, Gunterberg B et al (2000) Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients. Cancer 88:2122–2134CrossRefPubMed Bergh P, Kindblom LG, Gunterberg B et al (2000) Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients. Cancer 88:2122–2134CrossRefPubMed
3.
Zurück zum Zitat DeLaney TF, Liebsch NJ, Pedlow FX et al (2009) Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. Int J Radiat Oncol Biol Phys 74:732–739CrossRefPubMed DeLaney TF, Liebsch NJ, Pedlow FX et al (2009) Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. Int J Radiat Oncol Biol Phys 74:732–739CrossRefPubMed
4.
Zurück zum Zitat Stacchiotti S, Casali PG, Lo Vullo S et al (2010) Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers. Ann Surg Oncol 17:211–219. doi:10.1245/s10434-009-0740-x CrossRefPubMed Stacchiotti S, Casali PG, Lo Vullo S et al (2010) Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers. Ann Surg Oncol 17:211–219. doi:10.​1245/​s10434-009-0740-x CrossRefPubMed
5.
Zurück zum Zitat Casali PG, Messina A, Stacchiotti S et al (2004) Imatinib mesylate in chordoma. Cancer 101:2086–2097CrossRefPubMed Casali PG, Messina A, Stacchiotti S et al (2004) Imatinib mesylate in chordoma. Cancer 101:2086–2097CrossRefPubMed
6.
Zurück zum Zitat Stacchiotti S, Tamborini E, Lo Vullo S et al (2013) Phase II study on lapatinib in advanced EGFR-positive chordoma. Ann Oncol 24:1931–1936CrossRefPubMed Stacchiotti S, Tamborini E, Lo Vullo S et al (2013) Phase II study on lapatinib in advanced EGFR-positive chordoma. Ann Oncol 24:1931–1936CrossRefPubMed
7.
Zurück zum Zitat Hof H, Welzel T, Debus J (2006) Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma. Onkologie 29:572–574PubMed Hof H, Welzel T, Debus J (2006) Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma. Onkologie 29:572–574PubMed
8.
Zurück zum Zitat Akhavan-Sigari R, Gaab MR, Rohde V et al (2014) Prognostic significance of immunohistochemical expression of VEGFR2 and iNOS in spinal chordoma. Eur Spine J Off Publ Eur Spine Soc Eur Spinal Deform Soc Eur Sect Cerv Spine Res Soc 23:2416–2422. doi:10.1007/s00586-014-3417-5 CrossRef Akhavan-Sigari R, Gaab MR, Rohde V et al (2014) Prognostic significance of immunohistochemical expression of VEGFR2 and iNOS in spinal chordoma. Eur Spine J Off Publ Eur Spine Soc Eur Spinal Deform Soc Eur Sect Cerv Spine Res Soc 23:2416–2422. doi:10.​1007/​s00586-014-3417-5 CrossRef
9.
Zurück zum Zitat Von Witzleben A, Goerttler LT, Marienfeld R et al (2015) Preclinical characterization of novel chordoma cell systems and their targeting by pharmocological inhibitors of the CDK4/6 cell cycle pathway. Cancer Res. doi:10.1158/0008-5472.CAN-14-3270 Von Witzleben A, Goerttler LT, Marienfeld R et al (2015) Preclinical characterization of novel chordoma cell systems and their targeting by pharmocological inhibitors of the CDK4/6 cell cycle pathway. Cancer Res. doi:10.​1158/​0008-5472.​CAN-14-3270
10.
Zurück zum Zitat Noel G, Habrand JL, Mammar H et al (2001) Combination of photon and proton radiation therapy for chordomas and chondrosarcomas of the skull base: the Centre de Protontherapie D’Orsay experience. Int J Radiat Oncol Biol Phys 51:392–398CrossRefPubMed Noel G, Habrand JL, Mammar H et al (2001) Combination of photon and proton radiation therapy for chordomas and chondrosarcomas of the skull base: the Centre de Protontherapie D’Orsay experience. Int J Radiat Oncol Biol Phys 51:392–398CrossRefPubMed
11.
Zurück zum Zitat Ärztebl D (2003) 100(A):2251 (Heft 34–35 ) Ärztebl D (2003) 100(A):2251 (Heft 34–35 )
12.
Zurück zum Zitat Barth TFE, Martin-Subero JI, Joos S et al (2003) Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma. Blood 101:3681–3686CrossRefPubMed Barth TFE, Martin-Subero JI, Joos S et al (2003) Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma. Blood 101:3681–3686CrossRefPubMed
13.
Zurück zum Zitat Weniger MA, Pulford K, Gesk S et al (2006) Gains of the proto-oncogene BCL11A and nuclear accumulation of BCL11A(XL) protein are frequent in primary mediastinal B-cell lymphoma. Leukemia 20:1880–1882CrossRefPubMed Weniger MA, Pulford K, Gesk S et al (2006) Gains of the proto-oncogene BCL11A and nuclear accumulation of BCL11A(XL) protein are frequent in primary mediastinal B-cell lymphoma. Leukemia 20:1880–1882CrossRefPubMed
14.
Zurück zum Zitat Determann O, Hoster E, Ott G et al (2008) Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL network and the german low grade lymphoma study group. Blood 111:2385–2387. doi:10.1182/blood-2007-10-117010 CrossRefPubMed Determann O, Hoster E, Ott G et al (2008) Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL network and the german low grade lymphoma study group. Blood 111:2385–2387. doi:10.​1182/​blood-2007-10-117010 CrossRefPubMed
15.
Zurück zum Zitat Flanagan AMYT (2013) Chordoma. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F (eds) World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone. IARC Press, Lyon, pp 328–329 Flanagan AMYT (2013) Chordoma. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F (eds) World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone. IARC Press, Lyon, pp 328–329
16.
Zurück zum Zitat McMaster ML, Goldstein AM, Bromley CM et al (2001) Chordoma: incidence and survival patterns in the United States, 1973–1995. Cancer Causes Control CCC 12:1–11CrossRefPubMed McMaster ML, Goldstein AM, Bromley CM et al (2001) Chordoma: incidence and survival patterns in the United States, 1973–1995. Cancer Causes Control CCC 12:1–11CrossRefPubMed
17.
Zurück zum Zitat Shen J, Li C-D, Yang H-L et al (2011) Classic chordoma coexisting with benign notochordal cell rest demonstrating different immunohistological expression patterns of brachyury and galectin-3. J Clin Neurosci Off J Neurosurg Soc Australas 18:96–99. doi:10.1016/j.jocn.2010.03.066 Shen J, Li C-D, Yang H-L et al (2011) Classic chordoma coexisting with benign notochordal cell rest demonstrating different immunohistological expression patterns of brachyury and galectin-3. J Clin Neurosci Off J Neurosurg Soc Australas 18:96–99. doi:10.​1016/​j.​jocn.​2010.​03.​066
19.
Zurück zum Zitat Joshi VV (2000) Peripheral neuroblastic tumors: pathologic classification based on recommendations of international neuroblastoma pathology committee (Modification of shimada classification). Pediatr Dev Pathol Off J Soc Pediatr Pathol Paediatr Pathol Soc 3:184–199CrossRef Joshi VV (2000) Peripheral neuroblastic tumors: pathologic classification based on recommendations of international neuroblastoma pathology committee (Modification of shimada classification). Pediatr Dev Pathol Off J Soc Pediatr Pathol Paediatr Pathol Soc 3:184–199CrossRef
20.
Zurück zum Zitat Shimada H, Ambros IM, Dehner LP et al (1999) The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 86:364–372CrossRefPubMed Shimada H, Ambros IM, Dehner LP et al (1999) The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 86:364–372CrossRefPubMed
21.
Zurück zum Zitat Naka T, Boltze C, Kuester D et al (2005) Intralesional fibrous septum in chordoma: a clinicopathologic and immunohistochemical study of 122 lesions. Am J Clin Pathol 124:288–294CrossRefPubMed Naka T, Boltze C, Kuester D et al (2005) Intralesional fibrous septum in chordoma: a clinicopathologic and immunohistochemical study of 122 lesions. Am J Clin Pathol 124:288–294CrossRefPubMed
22.
Zurück zum Zitat Saad AG, Collins MH (2005) Prognostic value of MIB-1, E-cadherin, and CD44 in pediatric chordomas. Pediatr Dev Pathol Off J Soc Pediatr Pathol Paediatr Pathol Soc 8:362–368CrossRef Saad AG, Collins MH (2005) Prognostic value of MIB-1, E-cadherin, and CD44 in pediatric chordomas. Pediatr Dev Pathol Off J Soc Pediatr Pathol Paediatr Pathol Soc 8:362–368CrossRef
23.
Zurück zum Zitat Yakkioui Y, Temel Y, Creytens D et al (2014) A comparison of cell-cycle markers in skull base and sacral chordomas. World Neurosurg 82:e311–e318CrossRefPubMed Yakkioui Y, Temel Y, Creytens D et al (2014) A comparison of cell-cycle markers in skull base and sacral chordomas. World Neurosurg 82:e311–e318CrossRefPubMed
24.
Zurück zum Zitat Sakai K, Hongo K, Tanaka Y, Nakayama J (2007) Analysis of immunohistochemical expression of p53 and the proliferation marker Ki-67 antigen in skull base chordomas: relationships between their expression and prognosis. Brain Tumor Pathol 24:57–62CrossRefPubMed Sakai K, Hongo K, Tanaka Y, Nakayama J (2007) Analysis of immunohistochemical expression of p53 and the proliferation marker Ki-67 antigen in skull base chordomas: relationships between their expression and prognosis. Brain Tumor Pathol 24:57–62CrossRefPubMed
25.
Zurück zum Zitat Horbinski C, Oakley GJ, Cieply K et al (2010) The prognostic value of Ki-67, p53, epidermal growth factor receptor, 1p36, 9p21, 10q23, and 17p13 in skull base chordomas. Arch Pathol Lab Med 134:1170–1176PubMedPubMedCentral Horbinski C, Oakley GJ, Cieply K et al (2010) The prognostic value of Ki-67, p53, epidermal growth factor receptor, 1p36, 9p21, 10q23, and 17p13 in skull base chordomas. Arch Pathol Lab Med 134:1170–1176PubMedPubMedCentral
Metadaten
Titel
In chordoma, metastasis, recurrences, Ki-67 index, and a matrix-poor phenotype are associated with patients’ shorter overall survival
verfasst von
Adrian von Witzleben
Lukas T. Goerttler
Jochen Lennerz
Stephanie Weissinger
Marko Kornmann
Regine Mayer-Steinacker
Alexandra von Baer
Markus Schultheiss
Peter Möller
Thomas F. E. Barth
Publikationsdatum
23.09.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
European Spine Journal / Ausgabe 12/2016
Print ISSN: 0940-6719
Elektronische ISSN: 1432-0932
DOI
https://doi.org/10.1007/s00586-015-4242-1

Weitere Artikel der Ausgabe 12/2016

European Spine Journal 12/2016 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.